Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,288 shares of the company’s stock after buying an additional 209 shares during the quarter. Congress Wealth Management LLC DE’s holdings in Medpace were worth $4,082,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of MEDP. Vanguard Group Inc. lifted its position in shares of Medpace by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock valued at $854,087,000 after acquiring an additional 25,704 shares in the last quarter. State Street Corp raised its stake in Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Medpace by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after purchasing an additional 44,371 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares during the last quarter. Finally, American Capital Management Inc. grew its holdings in shares of Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after buying an additional 9,592 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $324.51 on Wednesday. The firm has a market capitalization of $9.89 billion, a PE ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The business has a 50-day moving average of $337.16 and a two-hundred day moving average of $339.57.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MEDP. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Leerink Partners started coverage on Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price target on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.